Skip to main content

Table 1 State of SLE patients included in the study

From: High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus

  SLE patients
  Quiescent disease (n= 33) Active disease (n= 37)
No. male/female 5/28 7/30
Age (years), median (range) 45 (19 to 73) 37 (18 to 73)
SLEDAI, median (range) 2 (0 to 4) 10 (5 to 16) ***
Anti-dsDNA (E/ml), median (range) 25 (3 to 408) 230 (3 to 6,683) ***
C3(g/l), median (range) 0.99 (0.54 to 1.46) 0.73 (0.21 to 1.68) ***
C4 (g/l), median (range) 0.15 (0.06 to 0.28) 0.12 (0.02 to 0.30) *
CRP (g/I), median (range) 5 (5 to 27) 6 (1 to 92)
No. with/without treatment 31/2 29/8
Users of Prednisone (%) Dose (mg/day), median (range) 19 (58%) 10 (2.5 to 50) 21 (57%) 7.50 (2.5 to 100)
Users of Azathioprine (%) Dose (mg/day), median (range) 8 (24%) 150 (50 to 150) 5 (14%) 100 (75 to 150)
Users of Hydroxychloroquine (%) Dose (mg/day), median (range) 19 (58%) 400 (150 to 600) 16 (43%) 400 (200 to 1,200)
  1. * Difference between quiescent and active SLE patients (* P < 0.05, ** P < 0.001, ***P < 0.0001).
\